SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years
22. September 2021 08:30 ET
|
Scynexis
First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including cloud-based pharmacyNew treatment is fungicidal against Candida species,...
SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)
13. September 2021 08:30 ET
|
Scynexis
JERSEY CITY, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Participate in Upcoming Investor Conferences
08. September 2021 08:30 ET
|
Scynexis
JERSEY CITY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update
16. August 2021 08:00 ET
|
Scynexis
BREXAFEMME® (ibrexafungerp tablets), the first novel antifungal class drug approved by the U.S. Food and Drug Administration (FDA) in more than 20 years, qualifies for 10 years of regulatory...
SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02. August 2021 17:00 ET
|
Scynexis
JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting
29. Juli 2021 08:00 ET
|
Scynexis
The pooled data from two Phase 3 studies (VANISH-303 and VANISH-306) of one-day oral ibrexafungerp reflect a population that overwhelmingly had severe yeast infections, a condition typically treated...
SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID
12. Juli 2021 08:00 ET
|
Scynexis
FURI and CARES presentations show ibrexafungerp’s strong clinical response in difficult-to-treat and refractory fungal infections in the hospital setting including Candida aurisIn vitro data...
SCYNEXIS to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
07. Juli 2021 08:30 ET
|
Scynexis
JERSEY CITY, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02. Juli 2021 16:01 ET
|
Scynexis
JERSEY CITY, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)
23. Juni 2021 08:30 ET
|
Scynexis
BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a...